Scalper1 News
Shares of Merck (MRK) rose 3% in after-hours trading after the company announced trial results that show best-selling diabetes treatment Januvia doesn’t increase the risk of stroke and other heart issues in diabetes patients. In adults with type 2 diabetes and a history of heart disease, the study found that the drug didn’t change the “composite of time” to the first occurrence of “cardiovascular-related death, nonfatal myocardial infarction, Scalper1 News
Scalper1 News